<center>**AMENDMENTS**</center>

<u>**Listing of Claims**</u>

The following listing of claims replaces all previous listings or versions thereof:

1.   (Currently amended) A bispecific antibody comprising three antibody variable domains on a single polypeptide chain, wherein:

a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, said first portion consisting of one antibody variable domain; and

a second portion of the bispecific antibody is capable of specifically binding to a target antigen other than the effector antigen, said target antigen being located on a target cell other than said human immune effector cell, and said second portion comprising two antibody variable domains,

<u>wherein the effector antigen is the human CD3 antigen, the target antigen is the human EpCAM antigen, and the bispecific antibody has a sequence as set forth in SEQ ID NO:1</u>.

2-49.   (Canceled)

50.   (Currently amended) A method for the prevention, treatment or amelioration of a proliferative disease[[,]]<u>or</u> a tumorous disease<s>, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host-disease or a host-versus-graft disease</s> in a subject in the need thereof, said method comprising the step of administration of an effective amount of a bispecific antibody of claim <u>1</u>.

51.   (Withdrawn) The method of claim 50, wherein said subject is a human.

52.   (Withdrawn) The method of claim 50, further comprising the administration of a proteinaceous compound capable of providing an activation signal for immune effector cells.

53.   (Withdrawn) The method of claim 52, wherein said proteinaceous compound is administered simultaneously or non-simultaneously with a bispecific antibody of any of claim 1.

54-55. (Canceled)

56.   (Currently amended) A kit comprising a bispecific antibody of [[of]] claim 1.

57.   (Canceled)